Overview of XPH ETF: The State Street SPDR S&P Pharmaceuticals ETF (XPH), launched in 2006, provides broad exposure to the Healthcare - Pharma sector, with assets over $208.47 million and a focus on matching the performance of the S&P Pharmaceuticals Select Industry Index.
Cost and Performance: With an annual operating expense of 0.35% and a 12-month trailing dividend yield of 0.92%, XPH has gained approximately 28.24% over the past year, making it a cost-effective option for investors seeking exposure to the pharmaceutical industry.
Risk and Diversification: The ETF has a beta of 0.61 and a standard deviation of 18.94%, indicating a higher risk profile, but it effectively diversifies company-specific risk with around 53 holdings, with 99.9% of its portfolio in the healthcare sector.
Comparison with Other ETFs: XPH carries a Zacks ETF Rank of 3 (Hold) and is compared to other ETFs like iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), which have larger asset bases and slightly different expense ratios.
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 57.020
Low
Averages
High
Current: 57.020
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
